Immune response and immunotherapy to Cryptococcus infections

Immunologic Research

Volumn 35, Issue 3, 2006, Pages 191-207

  Zhou, Qing ^a   Murphy, William J ^a,b  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEVADA   (United States)

Author keywords

Anti CD40; Cryptococcus neoformans; Immune response; Immunotherapy; Interleukin 2

Indexed keywords

AMPHOTERICIN B; ANTIBODY; ANTIFUNGAL AGENT; CD40 ANTIBODY; CHEMOKINE; CYTOKINE; FLUCONAZOLE; FLUCYTOSINE; FUNGUS VACCINE; GAMMA INTERFERON; GLUCURONOXYLOMANNAN; GLUCURONOXYLOMANNAN ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; MONOCLONAL ANTIBODY; NUCLEOSIDE DERIVATIVE; POLYENE ANTIBIOTIC AGENT; PYRROLE DERIVATIVE; RECOMBINANT GAMMA INTERFERON; TETANUS TOXOID; UNCLASSIFIED DRUG;

B LYMPHOCYTE; BONE MARROW SUPPRESSION; CARDIOVASCULAR DISEASE; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; CRYPTOCOCCOSIS; CRYPTOCOCCUS; CRYPTOCOCCUS NEOFORMANS; DENDRITIC CELL; ERYTHEMA NODOSUM LEPROSUM; HEMORRHAGIC EROSION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; INJECTION SITE REACTION; LIVER TOXICITY; LUNG EDEMA; LUNG INFECTION; MACROPHAGE; MICROGLIA; MONOCYTE; MONOTHERAPY; NATURAL KILLER CELL; NEUROLOGIC DISEASE; NEUTROPENIA; NEUTROPHIL; NONHUMAN; PERITONITIS; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VACCINATION;

ANIMALS; ANTIFUNGAL AGENTS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; HUMANS; IMMUNOTHERAPY;

EID: 33845869565     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:35:3:191     Document Type: Review

References (151)

1. Wilson LS, Reyes CM, Stolpman M, Speckman J, Allen K, Beney J: The direct cost and incidence of systemic fungal infections. Value Health 2002;5:26-34.
2. Perfect JR, Casadevall A: Cryptococcosis. Infect Dis Clin North Am 2002;16:837-874, v-vi.
3. Hajjeh RA, Conn LA, Stephens DS, et al: Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptococcal Active Surveillance Group. J Infect Dis 1999;179:449-454.
4. Subramanian S, Mathai D: Clinical manifestations and management of cryptococcal infection. J Postgrad Med 2005;51(Suppl): S21-S26.
5. Denning DW: Echinocandin antifungal drugs. Lancet 2003;362:1142-1151.
6. Johnson MD, Perfect JR: Caspofungin: first approved agent in a new class of antifungals. Expert Opin Pharmacother 2003;4:807-823.
7. Buchanan KL, Murphy JW: What makes Cryptococcus neoformans a pathogen? Emerg Infect Dis 1998;4:71-83.
8. Zaragoza O, Casadevall A: Experimental modulation of capsule size in Cryptococcus neoformans. Biol Proced Online 2004;6:10-15.
9. Levitz SM: Receptor-mediated recognition of Cryptococcus neoformans. Nippon Ishinkin Gakkai Zasshi 2002;43:133-136.
10. Yauch LE, Mansour MK, Levitz SM: Receptor-mediated clearance of Cryptococcus neoformans capsular polysaccharide in vivo. Infect Immun 2005;73:8429-8432.
11. Martinez LR, Moussai D, Casadevall A: Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen. Infect Immun 2004;72:3674-3679.
12. Feldmesser M, Tucker S, Casadevall A: Intracellular parasitism of macrophages by Cryptococcus neoformans. Trends Microbiol 2001;9:273-278.
13. Feldmesser M, Kress Y, Casadevall A: Intracellular crystal formation as a mechanism of cytotoxicity in murine pulmonary Cryptococcus neoformans infection. Infect Immun 2001;69:2723-2727.
14. Pericolini E, Monari C, et al: Cryptococcus neoformans capsular polysaccharide component galactoxylomannan induces apoptosis of human T-cells through activation of caspase-8. Cell Microbiol 2006;8:267-275.
15. Casadevall A, Rosas AL, Nosanchuk JD: Melanin and virulence in Cryptococcus neoformans. Curr Opin Microbiol 2000;3:354-358.
16. Huffnagle GB, Chen GH, Curtis JL, McDonald RA, Strieter RM, Toews GB. Down-regulation of the afferent phase of T cell-mediated pulmonary inflammation and immunity by a high melanin-producing strain of Cryptococcus neoformans. J Immunol 1995;155:3507-3516.
17. Wang Y, Casadevall A. Growth of Cryptococcus neoformans in presence of L-dopa decreases its susceptibility to amphotericin B. Antimicrob Agents Chemother 1994;38:2648-2650.
18. Ikeda R, Sugita T, Jacobson ES, Shinoda T: Effects of melanin upon susceptibility of Cryptococcus to antifungals. Microbiol Immunol 2003;47:271-277.
19. Levitz SM, North EA, Dupont MP, Harrison TS: Mechanisms of inhibition of Cryptococcus neoformans by human lymphocytes. Infect Immun 1995;63:3550-3554.
20. Levitz SM, Mathews HL, Murphy JW: Direct antimicrobial activity of T cells. Immunol Today 1995;16:387-391.
21. Levitz SM, Dupont MP, Smail EH: Direct activity of human T lymphocytes and natural killer cells against Cryptococcus neoformans. Infect Immun 1994;62:194-202.
22. Kawakami K, Kinjo Y, Yara S, et al: Enhanced gamma interferon production through activation of Valpha 14(+) natural killer T cells by alpha-galactosylceramide in interleukin-18-deficient mice with systemic cryptococcosis. Infect Immun 2001;69:6643-6650.
23. Murphy JW, Bistoni F, Deepe GS, et al: Type 1 and type 2 cytokines: from basic science to fungal infections. Med Mycol 1998;36(Suppl 1):109-118.
24. Koguchi Y, Kawakami K. Cryptococcal infection and Th1-Th2 cytokine balance. Int Rev Immunol 2002;21:423-438.
25. Mody CH, Lipscomb MF, Street NE, Toews GB: Depletion of CD4+ (L3T4+) lymphocytes in vivo impairs murine host defense to Cryptococcus neoformans. J Immunol 1990;144:1472-1477.
26. Hill JO, Dunn PL: A T cell-independent protective host response against Cryptococcus neoformans expressed at the primary site of infection in the lung. Infect Immun 1993;61:5302-5308.
27. Huffnagle GB, Yates JL, Lipscomb MF: Immunity to a pulmonary Cryptococcus neoformans infection requires both CD4+ and CD8+ T cells. J Exp Med 1991;173:793-800.
28. Brodie SJ, Sasseville VG, Reimann KA, Simon MA, Sehgal PK, Ringler DJ: Macrophage function in simian AIDS. Killing defects in vivo are independent of macrophage infection, associated with alterations in Th phenotype, and reversible with IFN-gamma. J Immunol 1994;153:5790-5801.
29. Buchanan KL, Doyle HA: Requirement for CD4(+) T lymphocytes in host resistance against Cryptococcus neoformans in the central nervous system of immunized mice. Infect Immun 2000;68:456-462.
30. Lipscomb MF, Huffnagle GB, Lovchik JA, Lyons CR, Pollard AM, Yates JL: The role of T lymphocytes in pulmonary microbial defense mechanisms. Arch Pathol Lab Med 1993;117:1225-1232.
31. Huffnagle GB, Lipscomb MF, Lovchik JA, Hoag KA, Street NE: The role of CD4+ and CD8+ T cells in the protective inflammatory response to a pulmonary cryptococcal infection. J Leukoc Biol 1994;55:35-42.
32. Ma LL, Spurrell JC, Wang JF, et al: CD8 T cell-mediated killing of Cryptococcus neoformans requires granulysin and is dependent on CD4 T cells and IL-15. J Immunol 2002;169:5787-5795.
33. Aguirre KM, Johnson LL. A role for B cells in resistance to Cryptococcus neoformans in mice. Infect Immun 1997;65:525-530.
34. Monga DP, Kumar R, Mohapatra LN, Malaviya AN: Experimental cryptococcosis in normal and B-cell-deficient mice. Infect Immun 1979;26:1-3.
35. Rosas AL, Nosanchuk JD, Casadevall A: Passive immunization with melanin-binding monoclonal antibodies prolongs survival of mice with lethal Cryptococcus neoformans infection. Infect Immun 2001;69:3410-3412.
36. Devi SJ: Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model. Vaccine 1996;14:841-844.
37. Feldmesser M, Mednick A, Casadevall A: Antibody-mediated protection in murine Cryptococcus neoformans infection is associated with pleotrophic effects on cytokine and leukocyte responses. Infect Immun 2002;70:1571-1580.
38. Kelly RM, Chen J, Yauch LE, Levitz SM: Opsonic requirements for dendritic cell-mediated responses to Cryptococcus neoformans. Infect Immun 2005;73:592-598.
39. Eng RH, Bishburg E, Smith SM, Kapila R: Cryptococcal infections in patients with acquired immune deficiency syndrome. Am J Med 1986;81:19-23.
40. Mozaffarian N, Berman JW, Casadevall A: Immune complexes increase nitric oxide production by interferon-gamma-stimulated murine macrophage-like J774.16 cells. J Leukoc Biol 1995;57:657-662.
41. Lee SC, Kress Y, Dickson DW, Casadevall A: Human microglia mediate anti-Cryptococcus neoformans activity in the presence of specific antibody. J Neuroimmunol 1995;62:43-52.
42. Rivera J, Mukherjee J, Weiss LM, Casadevall A: Antibody efficacy in murine pulmonary Cryptococcus neoformans infection: a role for nitric oxide. J Immunol 2002;168:3419-3427.
43. Goldman D, Song X, Kitai R, Casadevall A, Zhao ML, Lee SC: Cryptococcus neoformans induces macrophage inflammatory protein 1alpha (MIP-1alpha) and MIP-1beta in human microglia: role of specific antibody and soluble capsular polysaccharide. Infect Immun 2001;69:1808-1815.
44. Mukherjee J, Scharff MD, Casadevall A: Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immun 1992;60:4534-4541.
45. Dromer F, Charreire J, Contrepois A, Carbon C, Yeni P: Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody. Infect Immun 1987;55:749-752.
46. Vecchiarelli A, Pietrella D, Dottorini M, et al: Encapsulation of Cryptococcus neoformans regulates fungicidal activity and the antigen presentation process in human alveolar macrophages. Clin Exp Immunol 1994;98:217-223.
47. Vecchiarelli A, Dottorini M, Pietrella D, et al: Role of human alveolar macrophages as antigen-presenting cells in Cryptococcus neoformans infection. Am J Respir Cell Mol Biol 1994;11:130-137.
48. Gross NT, Camner P, Chinchilla M, Jarstrand C: In vitro effect of lung surfactant on alveolar macrophage defence mechanisms against Cryptococcus neoformans. Mycopathologia 1998;144:21-27.
49. Gross NT, Nessa K, Camner P, Jarstrand C: Production of nitric oxide by rat alveolar macrophages stimulated by Cryptococcus neoformans or Aspergillus fumigatus. Med Mycol 1999;37:151-157.
50. Shao X, Mednick A, Alvarez M, van RN, Casadevall A, Goldman DL: An innate immune system cell is a major determinant of species-related susceptibility differences to fungal pneumonia. J Immunol 2005;175:3244-3251.
51. Levitz SM, Tabuni A: Binding of Cryptococcus neoformans by human cultured macrophages. Requirements for multiple complement receptors and actin. J Clin Invest 1991;87:528-535.
52. Mansour MK, Schlesinger LS, Levitz SM: Optimal T cell responses to Cryptococcus neoformans mannoprotein are dependent on recognition of conjugated carbohydrates by mannose receptors. J Immunol 2002;168:2872-2879.
53. He W, Casadevall A, Lee SC, Goldman DL: Phagocytic activity and monocyte chemotactic protein expression by pulmonary macrophages in persistent pulmonary cryptococcosis. Infect Immun 2003;71:930-936.
54. Kawakami K, Qureshi MH, Zhang T, et al: Involvement of endogenously synthesized interleukin (IL)-18 in the protective effects of IL-12 against pulmonary infection with Cryptococcus neoformans in mice. FEMS Immunol Med Microbiol 2000;27:191-200.
55. Alspaugh JA, Granger DL: Inhibition of Cryptococcus neoformans replication by nitrogen oxides supports the role of these molecules as effectors of macrophage-mediated cytostasis. Infect Immun 1991;59:2291-2296.
56. Tohyama M, Kawakami K, Futenma M, Saito A: Enhancing effect of oxygen radical scavengers on murine macrophage anticryptococcal activity through production of nitric oxide. Clin Exp Immunol 1996;103:436-441.
57. Rossi GR, Cervi LA, Garcia MM, Chiapello LS, Sastre DA, Masih DT: Involvement of nitric oxide in protecting mechanism during experimental cryptococcosis. Clin Immunol 1999;90:256-265.
58. Aguirre KM, Gibson GW. Differing requirement for inducible nitric oxide synthase activity in clearance of primary and secondary Cryptococcus neoformans infection. Med Mycol 2000;38:343-353.
59. Mozaffarian N, Berman JW, Casadevall A: Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B. Antimicrob Agents Chemother 1997;41:1825-1829.
60. Aravalli RN, Hu S, Rowen TN, Palmquist JM, Lokensgard JR. Cutting edge: TLR2-mediated proinflammatory cytokine and chemokine production by microglial cells in response to herpes simplex virus. J Immunol 2005;175:4189-4193.
61. Cheeran MC, Hu S, Sheng WS, Rashid A, Peterson PK, Lokensgard JR: Differential responses of human brain cells to West Nile virus infection. J Neurovirol 2005;11:512-524.
62. Graeber MB, Scheithauer BW, Kreutzberg GW: Microglia in brain tumors. Gila 2002;40:252-259.
63. Taniguchi Y, Ono K, Yoshida S, Tanaka R: Antigen-presenting capability of glial cells under glioma-harboring conditions and the effect of glioma-derived factors on antigen presentation. J Neuroimmunol 2000;111:177-185.
64. Watters JJ, Schartner JM, Badie B: Microglia function in brain tumors. J Neurosci Res 2005;81:447-455.
65. Davalos D, Grutzendler J, Yang G, et al: ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci 2005;8:752-758.
66. Dommergues MA, Plaisant F, Verney C, Gressens P: Early microglial activation following neonatal excitotoxic brain damage in mice: a potential target for neuroprotection. Neuroscience 2003;121:619-628.
67. Rappert A, Bechmann I, Pivneva T, et al: CXCR3-dependent microglial recruitment is essential for dendrite loss after brain lesion. J Neurosci 2004;24:8500-8509.
68. Ponomarev ED, Novikova M, Maresz K, Shriver LP, Dittel BN: Development of a culture system that supports adult microglial cell proliferation and maintenance in the resting state. J Immunol Methods 2005;300:32-46.
69. Ponomarev ED, Shriver LP, Maresz K, Dittel BN: Microglial cell activation and proliferation precedes the onset of CNS autoimmunity. J Neurosci Res 2005;81:374-389.
70. Matyszak MK, Denis-Donini S, Citterio S, Longhi R, Granucci F, Ricciardi-Castagnoli P: Microglia induce myelin basic protein-specific T cell anergy or T cell activation, according to their state of activation. Eur J Immunol 1999;29:3063-3076.
71. Aguirre K, Miller S: MHC class II-positive perivascular microglial cells mediate resistance to Cryptococcus neoformans brain infection. Glia 2002;39:184-188.
72. Blasi E, Barluzzi R, Mazzolla R, et al: Role of nitric oxide and melanogenesis in the accomplishment of anticryptococcal activity by the BV-2 microglial cell line. J Neuroimmunol 1995;58:111-116.
73. Vremec D, Shortman K: Dendritic cell subtypes in mouse lymphoid organs: cross-correlation of surface markers, changes with incubation, and differences among thymus, spleen, and lymph nodes. J Immunol 1997;159:565-573.
74. Salomon B, Cohen JL, Masurier C, Klatzmann D: Three populations of mouse lymph node dendritic cells with different origins and dynamics. J Immunol 1998;160:708-717.
75. Shortman K, Wu L, Suss G, et al: Dendritic cells and T lymphocytes: developmental and functional interactions. Ciba Found Symp 1997;204:130-138.
76. Grewal IS, Borrow P, Pamer EG, Oldstone MB, Flavell RA: The CD40-CD154 system in anti-infective host defense. Curr Opin Immunol 1997;9:491-497.
77. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996;14:233-258.
78. Kronin V, Winkel K, Suss G, et al: A subclass of dendritic cells regulates the response of naive CD8 T cells by limiting their IL-2 production. J Immunol 1996;157:3819-3827.
79. Suss G, Shortman K: A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. J Exp Med 1996;183:1789-1796.
80. Inaba K, Pack M, Inaba M, Sakuta H, Isdell F, Steinman RM: High levels of a major histocompatibility complex II-self peptide complex on dendritic cells from the T cell areas of lymph nodes. J Exp Med 1997;186:665-672.
81. Syme RM, Spurrell JC, Amankwah EK, Green FH, Mody CH: Primary dendritic cells phagocytose Cryptococcus neoformans via mannose receptors and Fcgamma receptor II for presentation to T lymphocytes. Infect Immun 2002;70:5972-5981.
82. Mansour MK, Latz E, Levitz SM: Cryptococcus neoformans glycoantigens are captured by multiple lectin receptors and presented by dendritic cells. J Immunol 2006;176:3053-3061.
83. Pietrella D, Corbucci C, Perito S, Bistoni G, Vecchiarelli A: Mannoproteins from Cryptococcus neoformans promote dendritic cell maturation and activation. Infect Immun 2005;73:820-827.
84. Herring AC, Falkowski NR, Chen GH, McDonald RA, Toews GB, Huffnagle GB: Transient neutralization of tumor necrosis factor alpha can produce a chronic fungal infection in an immunocompetent host: potential role of immature dendritic cells. Infect Immun 2005;73:39-49.
85. Vecchiarelli A, Pietrella D, Lupo P, Bistoni F, McFadden DC, Casadevall A: The polysaccharid capsule of Cryptococcus neoformans interferes with human dendritic cell maturation and activation. J Leukoc Biol 2003;74:370-378.
86. Bauman SK, Nichols KL, Murphy JW: Dendritic cells in the induction of protective and nonprotective anticryptococcal cell-mediated immune responses. J Immunol 2000;165:158-167.
87. Gonzalez-Amaro R, Salazar-Gonzalez JF, Baranda L, et al: Natural killer cell-mediated cytotoxicity in cryptococcal meningitis. Rev Invest Clin 1991;43:133-138.
88. Hidore MR, Mislan TW, Murphy JW: Responses of murine natural killer cells to binding of the fungal target Cryptococcus neoformans. Infect Immun 1991;59:1489-1499.
89. Hidore MR, Nabavi N, Sonleitner F, Murphy JW: Murine natural killer cells are fungicidal to Cryptococcus neoformans. Infect Immun 1991;59:1747-1754.
90. Ma LL, Wang CL, Neely GG, Epelman S, Krensky AM, Mody CH: NK cell use perforin rather than granulysin for anticryptococcal activity. J Immunol 2004;173:3357-3365.
91. Kawakami K, Koguchi Y, Qureshi MH, et al: NK cells eliminate Cryptococcus neoformans by potentiating the fungicidal activity of macrophages rather than by directly killing them upon stimulation with IL-12 and IL-18. Microbiol Immunol 2000;44:1043-1050.
92. Murphy JW, Hidore MR, Nabavi N: Binding interactions of murine natural killer cells with the fungal target Cryptococcus neoformans. Infect Immun 1991;59:1476-1488.
93. Jackson LA, Drevets DA, Dong ZM, Greenfield RA, Murphy JW: Levels of L-selectin (CD62L) on human leukocytes in disseminated cryptococcosis with and without associated HIV-1 infection. J Infect Dis 2005;191:1361-1367.
94. Miller MF, Mitchell TG: Killing of Cryptococcus neoformans strains by human neutrophils and monocytes. Infect Immun 1991;59:24-28.
95. Babior BM, Curnutte JT, McMurrich BJ: The particulate superoxide-forming system from human neutrophils. Properties of the system and further evidence supporting its participation in the respiratory burst. J Clin Invest 1976;58:989-996.
96. Chaturvedi V, Wong B, Newman SL. Oxidative killing of Cryptococcus neoformans by human neutrophils. Evidence that fungal mannitol protects by scavenging reactive oxygen intermediates. J Immunol 1996;156:3836-3840.
97. Del Buono BJ, Luscinskas FW, Simons ER: Preparation and characterization of plasma membrane vesicles from human polymorphonuclear leukocytes. J Cell Physiol 1989;141:636-644.
98. Ganz T, Selsted ME, Szklarek D, et al: Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest 1985;76:1427-1435.
99. Steinbakk M, Naess-Andresen CF, Lingaas E, Dale I, Brandtzaeg P, Fagerhol MK: Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin. Lancet 1990;336:763-765.
100. Gadebusch HH, Johnson AG: Natural host resistance to infection with Cryptococcus neoformans. IV. The effect of some cationic proteins on the experimental disease. J Infect Dis 1966;116:551-565.
101. Vorland LH, Ulvatne H, Andersen J, et al: Antibacterial effects of lactoferricin B. Scand J Infect Dis 1999;31:179-184.
102. Vecchiarelli A, Retini C, Casadevall A, Monari C, Pietrella D, Kozel TR: Involvement of C3a and C5a in interleukin-8 secretion by human polymorphonuclear cells in response to capsular material of Cryptococcus neoformans. Infect Immun 1998;66:4324-4330.
103. Retini C, Vecchiarelli A, Monari C, Tascini C, Bistoni F, Kozel TR: Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils. Infect Immun 1996;64:2897-2903.
104. Mosmann TR, Sad S: The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996;17:138-146.
105. Herring AC, Lee J, McDonald RA, Toews GB, Huffnagle GB: Induction of interleukin-12 and gamma interferon requires tumor necrosis factor alpha for protective T1-cell-mediated immunity to pulmonary Cryptococcus neoformans infection. Infect Immun 2002;70:2959-2964.
106. Collins HL, Bancroft GJ: Cytokine enhancement of complement-dependent phagocytosis by macrophages: synergy of tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor for phagocytosis of Cryptococcus neoformans. Eur J Immunol 1992;22:1447-1454.
107. Bauman SK, Huffnagle GB, Murphy JW: Effects of tumor necrosis factor alpha on dendritic cell accumulation in lymph nodes draining the immunization site and the impact on the anticryptococcal cell-mediated immune response. Infect Immun 2003;71:68-74.
108. Banchereau J, Briere F, Caux C, et al: Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811.
109. Lovchik JA, Lyons CR, Lipscomb MF: A role for gamma interferon-induced nitric oxide in pulmonary clearance of Cryptococcus neoformans. Am J Respir Cell Mol Biol 1995;13:116-124.
110. Mody CH, Tyler CL, Sitrin RG, Jackson C, Toews GB: Interferon-gamma activates rat alveolar macrophages for anticryptococcal activity. Am J Respir Cell Mol Biol 1991;5:19-26.
111. Kawakami K, Kohno S, Kadota J, et al: T cell-dependent activation of macrophages and enhancement of their phagocytic activity in the lungs of mice inoculated with heat-killed Cryptococcus neoformans: involvement of IFN-gamma and its protective effect against crytococcal infection. Microbiol Immunol 1995;39:135-143.
112. Kawakami K, Qureshi MH, Zhang T, et al: Interferon-gamma (IFN-gamma)-dependent protection and synthesis of chemoattractants for mononuclear leucocytes caused by IL-12 in the lungs of mice infected with Cryptococcus neoformans. Clin Exp Immunol 1999;117:113-122.
113. Kleinschek MA, Muller U, Brodie SJ, et al: IL-23 enhances the inflammatory cell response in Cryptococcus neoformans infection and induces a cytokine pattern distinct from IL-12. J Immunol 2006;176:1098-1106.
114. Ellerbroek PM, Walenkamp AM, Hoepelman AI, Coenjaerts FE: Effects of the capsular polysaccharides of Cryptococcus neoformans on phangocyte migration and inflammatory mediators. Curr Med Chem 2004;11:253-266.
115. Vecchiarelli A, Retini C, Monari C, Tascini C, Bistoni F, Kozel TR: Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect Immun 1996;64:2846-2849.
116. Monari C, Retini C, Palazzetti B, Bistoni F, Vecchiarelli A: Regulatory role of exogenous IL-10 in the development of immune response versus Cryptococcus neoformans. Clin Exp Immunol 1997;109:242-247.
117. Mariano AR, Monteiro AG, Alexandre DG, ves Melo BC: Glucuronoxylomannan of Cryptococcus neoformans exacerbates in vitro yeast cell growth by interleukin 10-dependent inhibition of CD4+ T lymphocyte responses. Cell Immunol 2003;222:116-125.
118. Chiapello LS, Baronetti JL, Aoki MP, Gea S, Rubinstein H, Masih DT: Immunosuppression, interleukin-10 synthesis and apoptosis are induced in rats inoculated with Cryptococcus neoformans glucuronoxylomannan. Immunology 2004;113:392-400.
119. Blackstock R, Buchanan KL, Adesina AM, Murphy JW: Differential regulation of immune responses by highly and weakly virulent Cryptococcus neoformans isolates. Infect Immun 1999;67:3601-3609.
120. Blackstock R, Murphy JW: Role of interleukin-4 in resistance to Cryptococcus neoformans infection. Am J Respir Cell Mol Biol 2004;30:109-117.
121. Kawakami K, Hossain QM, Zang T, et al: Interleukin-4 weakens host resistance to pulmonary and disseminated cryptococcal infection caused by combined treatment with interferon-gamma-inducing cytokines. Cell Immunol 1999;197:55-61.
122. Shao X, Rivera J, Niang R, Casadevall A, Goldman DL: A dual role for TGF-betal in the control and persistence of fungal pneumonia. J Immunol 2005;175:6757-6763.
123. Huffnagle GB, Strieter RM, Standiford TJ, et al: The role of monocyte chemotactic protein-1 (MCP-1) in the recruitment of monocyes and CD4+ T cells during a pulmonary Cryptococcus neoformans infection. J Immunol 1995;155:4790-4797.
124. Huffnagle GB, Strieter RM, McNeil LK, et al: Macrophage inflammatory protein-1 alpha (MIP-1 alpha) is required for the efferent phase of pulmonary cell-mediated immunity to a Cryptococcus neoformans infection. J Immunol 1997;159:318-327.
125. Doyle HA, Murphy JW: MIP-1 alpha contributes to the anticryptococcal delayed-type hypersensitivity reaction and protection against Cryptococcus neoformans. J Leukoc Biol 1997;61:147-155.
126. Marfaing-Koka A, Devergne O, Gorgone G, et al: Regulation of the production of the RANTES chemokine by endothelial cells. Synergistic induction by IFN-gamma plus TNF-alpha and inhibition by IL-4 and IL-13. J Immunol 1995;154:1870-1878.
127. Devergne O, Marfaing-Koka A, Schall TJ, et al: Production of the RANTES chemokine in delayed-type hypersensitivity reactions: involvement of macrophages and endothelial cells. J Exp Med 1994;179:1689-1694.
128. Traynor TR, Herring AC, Dorf ME, Kuziel WA, Toews GB, Huffnagle GB: Differential roles of CC chemokine ligand 2/monocyte chemotactic protein-1 and CCR2 in the development of T1 immunity. J Immunol 2002;168:4659-4666.
129. Huffnagle GB, McNeil LK, McDonald RA, et al: Cutting edge: role of C-C chemokine receptor 5 in organ-specific and innate immunity to Cryptococcus neoformans. J Immunol 1999;163:4642-4646.
130. Uicker WC, Doyle HA, McCracken JP, Langlois M, Buchanan KL: Cytokine and chemokine expression in the central nervous system associated with protective cell-mediated immunity against Cryptococcus neoformans. Med Mycol 2005;43:27-38.
131. Maffei CM, Mirels LF, Sobel RA, Clemons KV, Stevens DA: Cytokine and inducible nitric oxide synthase mRNA expession during experimental murine cryptococcal meningoencephalitis. Infect Immun 2004;72:2338-2349.
132. Devi SJ, Hayat U, Powell JL, Morris JG, Jr: Preclinical immunoprophylactic and immunotherapeutic efficacy of antisera to capsular polysaccharide-tetanus toxoid conjugate vaccines of Vibrio vulnificus. Infect Immun 1996;64:2220-2224.
133. Siddiqui AA, Brouwer AE, Wuthiekanun V, et al: IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis. J Immunol 2005;174:1746-1750.
134. Netea MG, Brouwer AE, Hoogendoorn EH, et al: Two patients with cryptococcal meningitis and idiopathic CD4 lymphopenia: defective cytokine production and reversal by recombinant interferon- gamma therapy. Clin Infect Dis 2004;39:e83-e87.
135. Harrison TS, Levitz SM: Priming with IFN-gamma restores deficient IL-12 production by peripheral blood mononuclear cells from HIV-seropositive donors. J Immunol 1997;158:459-463.
136. Bava AJ, Afeltra J, Negroni R, Diez RA: Interferon gamma increases survival in murine experimental cryptococcosis. Rev Inst Med Trop Sao Paulo 1995;37:391-396.
137. Kawakami K, Tohyama M, Teruya K, Kudeken N, Xie Q, Saito A: Contribution of interferon-gamma in protecting mice during pulmonary and disseminated infection with Cryptococcus neoformans. FEMS Immunol Med Microbiol 1996;13:123-130.
138. Lutz JE, Clemons KV, Stevens DA: Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemic cryptococcosis. J Antimicrob Chemother 2000;46:437-442.
139. Kullberg BJ: Trends in immunotherapy of fungal infections. Eur J Clin Microbiol Infect Dis 1997;16:51-55.
140. Clemons KV, Lutz JE, Stevens DA: Efficacy of recombinant gamma interferon for treatment of systemic cryptococcosis in SCID mice. Antimicrob Agents Chemother 2001;45:686-689.
141. Kawakami K, Tohyama M, Xie Q, Saito A: IL-12 protects mice against pulmonary and disseminated infection caused by Cryptococcus neoformans. Clin Exp Immunol 1996;104:208-214.
142. Clemons KV, Brummer E, Stevens DA: Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Antimicrob Agents Chemother 1994;38:460-464.
143. Kawakami K, Koguchi Y, Qureshi MH, et al: IL-18 contributes to host resistance against infection with Cryptococcus neoformans in mice with defective IL-12 synthesis through induction of IFN-gamma production by NK cells. J Immunol 2000;165:941-947.
144. Kawakami K, Qureshi MH, Zhang T, Okamura H, Kurimoto M, Saito A. IL-18 protects mice against pulmonary and disseminated infection with Cryptococcus neoformans by inducing IFN-gamma production. J Immunol 1997;159:5528-5534.
145. Pietrella D, Perito S, Bistoni F, Vecchiarelli A: Cytotoxic T lymphocyte antigen costimulation influences T-cell activation in response to Cryptococcus neoformans. Infect Immun 2001;69:1508-1514.
146. Hori T: Roles of OX40 in the pathogenesis and the control of diseases. Int J Hematol 2006;83:17-22.
147. Humphreys IR, Edwards L, Walzl G, et al: OX40 ligation on activated T cells enhances the control of Cryptococcus neoformans and reduces pulmonary eosinophilia. J Immunol 2003;170:6125-6132.
148. Pietrella D, Lupo P, Perito S, Mosci P, Bistoni F, Vecchiarelli A: Disruption of CD40/CD40L interaction influences the course of Cryptococcus neoformans infection. FEMS Immunol Med Microbiol 2004;40:63-70.
149. Vecchiarelli A, Retini C, Pietrella D, Monari C, Kozel TR: T lymphocyte and monocyte interaction by CD40/CD40 ligand facilitates a lymphoproliferative response and killing of Cryptococcus neoformans in vitro. Eur J Immunol 2000;30:1385-1393.
150. Zhou Q, Gault RA, Kozel TR, Murphy WJ: Immunomodulation with CD40 stimulation and interleukin-2 protects mice from disseminated cryptococcosis. Infect Immun 2006;74:2161-2168.
151. Casadevall A, Pirofski LA: Feasibility and prospects for a vaccine to prevent cryptococcosis. Med Mycol 2005;43:667-680.